Tyrosine kinase inhibitors, such as axitinib, can perturb VEGF pathways by blocking the autophosphorylation of VEGF receptors [13], and are used in clinical studies against various tumour diseases [14,15]. The gene discussed is VEGFA; the disease is neoplasm.